Indication
Treatment of adult patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
Loading your page…
Loading your page…
Carcinoma, Non-Small-Cell Lung
Marketing Authorisation Holder: Takeda Pharma A/S
INN: mobocertinib
AI Drug & Interaction Analysis
Free account required
Ask Osler about Exkivity: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.